This miRNA sensitizes (p < 0.005) luminal and HER2-positive BC cells to CDK 4/6 treatment, as its targets include genes related to cell cycle progression, mitosis, and glycolysis [56]. This evidence concerns the gene ERBB2 and breast cancer.